Table 1.
Characteristics of the study participants (n = 131).
| Values | ||||
|---|---|---|---|---|
| Variable | Overall | <6 Weeks Interval between the Doses (Group I), n = 23 | 7–12 Weeks Interval between the Doses (Group II), n = 52 | 13–36 Weeks Interval between the Doses (Group III), n = 56 |
| Males (%) | 93 (71) | 20 (87) | 41 (79) | 32 (57) |
| Age (years) | 50 (43–58) | 58 (44–64) | 48 (40–57) | 51 (44–56) |
| Associated conditions | ||||
| Diabetes mellitus (DM) | 13 (9.9) | 3 | 5 | 5 |
| Hypertension (HTN) | 3 (2.3) | 1 | 1 | 1 |
| DM + HTN | 2 (1.5) | 1 | 0 | 1 |
| Etiology of cirrhosis | ||||
| Alcohol-related etiology | 14 (10.7) | 0 | 7 | 7 |
| Hepatitis B virus | 33 (25.2) | 7 | 11 | 15 |
| Hepatitis C virus | 46 (35.1) | 5 | 19 | 22 |
| Cryptogenic | 21 (16.0) | 7 | 7 | 7 |
| Autoimmune hepatitis | 9 (6.9) | 2 | 4 | 3 |
| Others | 8 (6.1 | 2 | 4 | 2 |
| Severity of liver cirrhosis | ||||
| Decompensated cirrhosis | 80 (61.1) | 15 (65) | 27 (52) | 38 (68) |
| Child–Turcotte–Pugh score | 7 (6–8) | 7 (5–8) | 7 (6–8) | 7 (6–9) |
| Child–Turcotte–Pugh Class | ||||
| CTP A | 52 (39.7) | 10 | 24 | 18 |
| CTP B | 63 (48.1) | 12 | 21 | 30 |
| CTP C | 16 (12.2) | 1 | 7 | 8 |
| Hemoglobin (g/dL) | 12.3 (10.7–13.8) | 12.9 (10.9–13.6) | 12.3 (10.6–13.2) | 12.3 (10.5–14.0) |
| While cell counts (×1000/mm3) | 4.9 (3.9–6.8) | 4.7 (3.9–6.5) | 5.0 (4.2–6.9) | 5.0 (3.7–6.9) |
| Platelets counts (×1000/µL) | 110 (71–140) | 110 (75–150) | 110 (80–139) | 101 (66–144) |
| Serum creatinine (mg/dL) | 0.9 (0.8–1.1) | 0.9 (0.8–1.0) | 0.9 (0.7–1.0) | 0.9 (0.8–1.1) |
| Total serum bilirubin (mg/dL) | 1.2 (0.8–2.0) | 1.0 (0.6–1.7) | 1.3 (0.9–2.5) | 1.2 (0.8–1.8) |
| Alanine aminotransferase (IU/L) | 35 (29–55) | 38 (31–55) | 33 (28–56) | 37 (30–53) |
| Aspartate aminotransferase (IU/L) | 48 (34–69) | 44 (27–66) | 44 (35–68) | 52 (38–74) |
| Serum total protein (g/dL) | 7.7 (7.2–8.2) | 7.8 (6.9–8.2) | 7.5 (7.1–8.2) | 7.8 (7.3–8.5) |
| Serum albumin (g/dL) | 4.1 (3.5–4.5) | 4.3 (3.6–4.7) | 4.1 (3.5–4.5) | 4.0 (3.6–4.4) |
| International normalized ratio (INR) | 1.28 (1.1–1.56) | 1.22 (1.10–1.54) | 1.28 (1.10–1.48) | 1.3 (1.07–1.59) |
| Liver stiffness as measured by transient elastography (kPa) # | 25.9 (15.9–43.5) | 25.1 (15.8–38.5) | 27.4 (17.3–44.9) | 24.9 (15.6–45.1) |
| Interval between two doses (weeks) | 12 (9–19) | 4 (4–5) | 12 (11–12) | 22 (16–24) |
| Interval between second dose and specimen collection (weeks) | 8 (5–12) | 8 (9–12) | 7 (4–12) | 7 (5–11) |
Categorical data are presented as number (proportions); Numerical data are expressed as median (interquartile range); # liver stiffness values were available for a total of 110 participants (22 group I, 44 group II, and 44 group III).